Plasma Osteopontin Correlates with Glycemic Control in Type 2 Diabetes Mellitus Patients
DOI:
https://doi.org/10.24293/ijcpml.v27i2.1638Keywords:
Type 2 DM, osteopontin, total 25-OH vitamin DAbstract
Diabetes Mellitus (DM) is a metabolic disease characterized by hyperglycemia due to abnormal secretions and/or insulin activity. Osteopontin (OPN) is an important component of inflammation and insulin resistance, and vitamin D decreases insulin resistance. This study aimed to analyze the correlation between OPN and glycemic control and total 25-OH vitamin D in type 2 DM. An observational analytic study with a cross-sectional approach was performed in Dr. Moewardi Hospital, Surakarta, from May to September 2018. Plasma OPN levels were measured by a sandwich enzyme immunoassay kit from Elabscience 96T Human OPN (USA), and a total of 25-OH vitamin D was evaluated using the ELFA method from Biomerieux SA (France). Data were tested by Pearson correlation (r). Type 2 DM subjects consisted of 45 (54.2%) males and 38 (45.8%) females, 36 (43.45%) well- and 47 (56.65%) poorly-controlled. The average age was 56.81±9.76 years old. The mean of OPN level in poorly-controlled cases was significantly higher (20.27±3.20 ng/mL) than well-controlled ones (15.04±3.34 ng/mL) with p=0.001. There was no significant difference in total 25-OH vitamin D between well- and poorly-controlled groups (19.84±6.65 vs. 17.24±6.78 ng/mL, respectively, p=0.085). The correlation of OPN with glycemic control (fasting glucose, 2-hour post-prandial glucose, HbA1c) and total 25-OH vitamin D in all subjects with type 2 DM were r=0.241 (p=0.028), r=0.378 (p=0.0001) r=0.529 (p=0.0001) and r=-0.151 (p=0.173), respectively. This study suggested that plasma OPN level was correlated with glycemic control but not with serum total 25-OH vitamin D in type 2 DM. Further research was needed in populations of other types of DM and other research variables related to inflammation or insulin resistance.
Downloads
References
American Diabetes Association (ADA). Standards of medical care in diabetes-2018. Diabetes Care, 2018; 41(1): S13-S27.
Perkeni. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019.
Jakarta, PB Perkeni, 2019; 1-50.
Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. th Williams textbook of endocrinology. 13 Ed., Philadelphia, Elsevier, 2016; 1386-1450.
Brownlee M, Aiello LP, Cooper ME, Vinik AI, Plutzky J, Boulton AJM. Complications of diabetes mellitus. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. th Williams textbook of endocrinology. 13 Ed.,
Philadelphia, Elsevier, 2016; 1484-1581.
Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: A systematic review. Eur J Clin Nutr, 2011; 65(9): 1005–1015.
Gravallese EM. Osteopontin: A bridge between bone and the immune system. J. Clin. Invest, 2003; 112: 147-149.
de Fusco C, Messina A, Monda V, Viggiano E, Moscatelli F, et al. Osteopontin: Relation between
adipose tissue and bone homeostasis. Stem Cells International, 2017; 2017: 1-6.
Sase SP, Ganu JV, Nagano N. Osteopontin: A novel protein molecule. Indian Medical Gazette, 2012; 62-66.
Agah E, Zardui A, Saghazadeh A, Ahmadi M, Tafakhori A, Rezaei N. Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis. PLoS One, 2018; 13(1): e0190252.
Van Driel M, Pols HAP, van Leeuwen JPTM. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Current Pharmaceutical Design, 2004; 10(00): 1-21.
Al-qtaitat AI, Aldalaen SM. A review of non-collagenous proteins; their role in bone. AJLS, 2014; 2(6): 351-355.
Thurner PJ, Chen CG, Lonova-Martin S, Sun L, Harman A, et al. Osteopontin deficiency increases
bone fragility but preserves bone mass. Bone, 2010; 46: 1564–1573.
Kahles F, Finfeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross-roads of inflammation, obesity, and diabetes. Molecular Metabolism, 2014; 3: 384-393.
Musialik K, Skrypnik D, Dogdanski P, Szulinska M. Osteopontin-a multifunctional protein and its impact on an insulin resistance development. J Med Sci, 2014; 2(83): 173-176.
Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, molecular
mechanism of action, and pleiotropic effects. Physiol Rev, 2016; 96: 365-408.
Gil A, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and novel actions. Ann Nutr Metab, 2018; 72: 87-95.
Battault S, Whiting SJ, Peltier SL, Sadrin S, Gerber G, Maixent JM. Vitamin D metabolism, functions and needs: From science to health claims. Eur J Nutr, 2012; 52(2): 1-14.
Boyraz I, Bilge U, Unalacak M, Bilgin M. A comparison of 25(OH) vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment. Biomed Res, 2016; 27(1): 1-5.
Berezin AE, Kremzer AA. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known a s y m pto m a ti c coron a r y a rt e r y di s e a s e .
Atherosclerosis, 2013; 229: 475-481.
Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, et al. Osteopontin deficiency
produces osteoclast dysfunction due to reduced CD44 surface expression. Mol. Biol. Cell, 2003; 14: 173-189.
Maser RE, Lenhard MJ, Pohlig RT, Balagopal PB. Osteopontin and osteoprotegerin levels in type 2
diabetes and their association with autonomic function. J Diabetes Complications, 2016; 30(3):507-510.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
